Univariate linear regression for VIQ
| Variable | n (mean; SD) | Mean VIQ (SD) | F† | p† |
|---|---|---|---|---|
| *Significant factors in univariate regression model. | ||||
| †F test based on type III sums of squares and p values show significance of variable in model. | ||||
| The continuous variables included were of normal distribution and the standardised residuals in all analysis were normally distributed. | ||||
| IGE, idiopathic generalised epilepsy; LD, learning difficulties; SES, socioeconomic status. | ||||
| Maternal age* | 248 (26.1; 4.8) | 90.7 (16.5) | 12.672 | 0.000 |
| Maternal FSIQ (NART)* | 247 (98.7; 11.5) | 90.7 (16.5) | 69.979 | 0.000 |
| SES* | Professional (reference) 48 | 98.8 (19.7) | 8.248 | 0.000 |
| Intermediate 48 | 91.4 (15.0) | |||
| Manual or never worked 149 | 88.1 (14.8) | |||
| Epilepsy type | Focal (reference) 166 | 92.0 (16.7) | 1.761 | 0.186 |
| IGE 75 | 89.0 (15.7) | |||
| Family history of LD in first degree relative | None (reference) 205 | 91.5 (16.7) | 3.215 | 0.074 |
| 1 or more 44 | 86.6 (15.90) | |||
| Regular smoking | None (reference) 181 | 91.4 (16.6) | 1.582 | 0.210 |
| Regular 68 | 88.5 (16.1) | |||
| Seizures in pregnancy | None (reference) 112 | 93.2 (17.7) | 3.126 | 0.026 |
| None, convulsive 49 | 90.2 (15.3) | |||
| 1–4 tonic-clonic seizures 46 | 90.1 (12.4) | |||
| 5 or more tonic-clonic seizures 42 | 84.4 (6.8) | |||
| AED in utero | Unexposed (reference) 80 | 90.9 (6.5) | 3.884 | 0.004 |
| Valproate 41 | 83.6 (17.1) | |||
| Carbamazepine 52 | 94.1 (16.0) | |||
| Phenytoin 21 | 98.5 (17.4) | |||
| Polytherapy 49 | 89.2 (14.2) | |||
| Regular folic acid | None (reference) 134 | 90.9 (15.5) | 0.109 | 0.742 |
| Regular (any dose) 115 | 90.2 (17.6) | |||